Fenofibrate-induced liver injury [2]

World Journal of Gastroenterology

Volumn 11, Issue 48, 2005, Pages 7702-7703

  Dohmen, Kazufumi ^a   Wen, Chun Yang ^b   Nagaoka, Shinya ^b   Yano, Koji ^b   Abiru, Seigo ^b   Ueki, Toshihito ^b   Komori, Atsumasa ^b   Daikoku, Manabu ^b   Yatsuhashi, Hiroshi ^b   Ishibashi, Hiromi ^b  

^a Okabe Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; MITOCHONDRION ANTIBODY; PYRUVATE DEHYDROGENASE COMPLEX;

AGED; BASOPHIL; CASE REPORT; DRUG WITHDRAWAL; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; LETTER; LEUKOCYTE COUNT; LIVER INJURY; LYMPHOCYTE; MONOCYTE; NEUTROPHIL; PRIMARY BILIARY CIRRHOSIS;

EID: 31644443255     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i48.7702     Document Type: Letter

References (9)

1. Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97: 2147-2149
2. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10: 894-898
3. Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36: 454-458
4. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95: 326-327
5. Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000; 47: 1518-1521
6. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95: 2990-2992
7. Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002; 97: 1075-1077
8. Diabetes Arteriosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Arteriosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905-910
9. Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett 1998; 98: 13-23